PMID- 15370723
OWN - NLM
STAT- MEDLINE
DCOM- 20041109
LR  - 20181130
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 33
IP  - 4
DP  - 2004
TI  - Etoricoxib reduced pain and disability and improved quality of life in patients 
      with chronic low back pain: a 3 month, randomized, controlled trial.
PG  - 257-66
AB  - BACKGROUND: Chronic low back pain (LBP) is a growing health problem. 
      Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat this condition, 
      but have not demonstrated efficacy beyond 2 weeks, and no studies have shown that 
      NSAIDs produce durable improvements in disability. METHODS: To evaluate the 
      efficacy and durability of effect of etoricoxib for chronic LBP, a randomized, 
      double blind, placebo-controlled trial was conducted at 46 centres. Three hundred 
      and twenty-five patients with chronic LBP requiring treatment with an NSAID or 
      paracetamol were randomized 1:1:1 to etoricoxib 60 mg (n=109), 90 mg (n=106), or 
      placebo (n=110), daily for 3 months. Pre-specified endpoints over 3 months 
      included LBP intensity scale (visual analog scale 0-100 mm) time-weighted average 
      change from baseline, the Roland-Morris Disability Questionnaire (RMDQ), the LBP 
      bothersomeness scale, patient and investigator global assessments, and measures 
      of quality of life. RESULTS: Both etoricoxib groups experienced significant 
      reductions in LBP intensity at 4 weeks versus placebo [-15.15 mm and -13.03 mm 
      for 60 and 90 mg, respectively, probability (p)<0.001 for each], which was 
      maintained over 3 months. Treatment resulted in significant improvement from 
      baseline compared to placebo in RMDQ scores (etoricoxib 60 mg, -2.82 and 90 mg, 
      -2.38, p<0.001 for each) over 12 weeks and most other efficacy endpoints. There 
      were no significant differences between treatments in incidence of adverse events 
      (AEs) or discontinuations due to AEs. CONCLUSION: Etoricoxib provided significant 
      relief of symptoms and disability associated with chronic LBP detected at 1 week, 
      confirmed at 4 weeks, and maintained over 3 months. Reductions in chronic LBP 
      severity corresponded to improvements in physical functioning and quality of 
      life. All treatments were generally well tolerated.
FAU - Pallay, R M
AU  - Pallay RM
AD  - Robert Wood Johnson University Medical Group PCC at Hillsboro, NJ, USA.
FAU - Seger, W
AU  - Seger W
FAU - Adler, J L
AU  - Adler JL
FAU - Ettlinger, R E
AU  - Ettlinger RE
FAU - Quaidoo, E A
AU  - Quaidoo EA
FAU - Lipetz, R
AU  - Lipetz R
FAU - O'Brien, K
AU  - O'Brien K
FAU - Mucciola, L
AU  - Mucciola L
FAU - Skalky, C S
AU  - Skalky CS
FAU - Petruschke, R A
AU  - Petruschke RA
FAU - Bohidar, N R
AU  - Bohidar NR
FAU - Geba, G P
AU  - Geba GP
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (Placebos)
RN  - 0 (Pyridines)
RN  - 0 (Sulfones)
RN  - WRX4NFY03R (Etoricoxib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chronic Disease
MH  - Disabled Persons
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Etoricoxib
MH  - Female
MH  - Humans
MH  - Low Back Pain/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Pyridines/administration & dosage/*therapeutic use
MH  - *Quality of Life
MH  - Sulfones/administration & dosage/*therapeutic use
MH  - Treatment Outcome
EDAT- 2004/09/17 05:00
MHDA- 2004/11/13 09:00
CRDT- 2004/09/17 05:00
PHST- 2004/09/17 05:00 [pubmed]
PHST- 2004/11/13 09:00 [medline]
PHST- 2004/09/17 05:00 [entrez]
AID - XKGAYKLQV515E2E8 [pii]
AID - 10.1080/03009740410005728 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 2004;33(4):257-66. doi: 10.1080/03009740410005728.